CoChat
Sign Up
Cited by 161Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index.

Association of metabolic syndrome and chronic kidney disease

Open access
Scurt, Florian G., Ganz, Maximilian J., Herzog, Carolin, Bose, Katrin, Mertens, Peter R., Chatzikyrkou, Christos·2024·Obesity Reviews
DOI 10.1111/obr.13649
Open this paper in CoChat — free account

Abstract

The prevalence of kidney disease is increasing rapidly worldwide, reflecting rising rates of obesity, diabetes, and associated metabolic syndrome (MetS). Chronic kidney disease and related comorbidities such as obesity, diabetes, and hypertension place a significant financial burden on healthcare systems. Despite the widespread use of RAAS inhibitors, intensive blood pressure and glycemic control, and newer therapeutic options consisting of sodium/glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists, a significant risk of progression to end-stage renal disease remains in the high-risk obese and diabetic population. The MetS is a cluster of cardiovascular risk factors that adversely affect the development and progression of chronic kidney failure. According to the criteria of the World Health Organization, it is defined by visceral adiposity, impaired glucose tolerance or insulin resistance, atherogenic dyslipidemia, raised blood pressure, and microalbuminuria with a albumin-to-creatinine ratio ≥30 mg/g. At molecular level MetS is marked by a proinflammatory state and increased oxidative stress leading to various pathophysiological changes causing endothelial dysfunction and a hypercoagulable state. Because the kidney is a highly vascularized organ, it is especially susceptible for those microvascular changes. Therefore, the MetS and its individual components are associated with the premature development, acceleration, and progressio…

Overview

Integrity signals

Registry

Crossref · 10.1111/obr.13649

Cites

162 of 162 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 165 references

Research works printed but not linked: 4

  1. World Health O, 1999, Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus
  2. Aihara K, 2010, Transforming growth factor‐β1 as a common target molecule for development of cardiovascular diseases, renal insufficiency and metabolic syndrome, Cardiol Res Pract, 2011
  3. Scurt FG, 2020, Paradigm shift in understanding acute kidney injury in patients with chronic liver disease: from pathophysiology to defining disease entities, Z Gastroenterol, 58, 254
  4. McMurray JJV, 2020, Dapagliflozin in patients with heart failure and reduced ejection fraction, Reply N Engl J Med, 382, 973

Cited by

Sorted by citations

See all 161

Related

Metadata

Authors
Scurt, F. G., Ganz, M. J., Herzog, C., Bose, K., Mertens, P. R., & Chatzikyrkou, C.
Affiliations
  • University Clinic for Nephrology and Hypertension, Diabetology and Endocrinology (DE)
  • Klinikum Magdeburg (DE)
  • Medizinische Hochschule Hannover (DE)
Corresponding author
Scurt, Florian G.
ORCID
Venue
Obesity Reviews
Publisher
Wiley
Published
2023-10-02
Volume
25
Issue
1
Pages
e13649-e13649
ISSN
  • 1467-7881 (ISSN-L)
  • 1467-789X
DOI
10.1111/obr.13649
OpenAlex
W4387246542
Cited by
155
References
165
Citations by year
2026: 50 · 2025: 75 · 2024: 29 · 2023: 1
FWCI
6.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Obesity Reviews (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
metabolic syndrome, chronic kidney disease, obesity, diabetes mellitus, insulin resistance, microalbuminuria, endothelial dysfunction, oxidative stress, inflammation, end-stage renal disease, renal hemodynamics, renal metabolism, SGLT2 inhibitors, GLP-1 receptor agonists, renin-angiotensin system inhibitors
MeSH terms
Diabetes Mellitus, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review